The recent clinical success achieved with immune checkpoint inhibitors, for example, by using blocking antibodies against programmed cell death ligand 1 (PD-L1), programmed death-1 (PD-1), and cytotoxic T lymphocyte antigen-4 (CTLA-4), illustrates the potential of the immune system in the elimination of cancer cells. The gene discussed is PDCD1; the disease is cancer.